Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Innovation Pharma completes enrollment in mid-stage study of Brilacidin in oral mucositis, top-line data expected in Q4

Published 08/07/2017, 07:03 AM
© Reuters.  Innovation Pharma completes enrollment in mid-stage study of Brilacidin in oral mucositis, top-line data expected in Q4
  • Innovation Pharmaceuticals (OTCQB:IPIX) hits the enrollment target of 61 subjects in its Phase 2 clinical trial evaluating an oral rinse formulation of Brilacidin for the prevention of severe oral mucositis (OM), a painful side-effect of chemoradiation in patients with head and neck cancer. Top-line results should be available in Q4.
  • Brilacidin is a member of a new class of antibiotics called defensin-mimetics which are modeled after host defense proteins. These are the "front line" of defense in the human immune system.
  • Now read: Seres Therapeutics Share Price Rise Over Past Month; Q2 Earnings Steady As You Go


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.